Table 4. Inclusion and exclusion criteria for the cross-sectional cohorts for the DOLORisk protocol.

	Inclusion criteria	Exclusion criteria
Peripheral neuropathic pain	•   ≥18 years with a diagnosis of peripheral neuropathy      based on a prior clinical assessment combined with      supportive clinical investigations such as abnormal nerve      conduction studies, reduced intraepidermal nerve or      abnormal findings on quantitative sensory testing. •   Symptoms highly suggestive of neuropathy that in the      judgement of the clinical researcher are suitable for the      study even if they do not fulfil other inclusion criteria. •   Patients who do not fulfil any of the exclusion criteria. •   Diabetes cohorts: Type 1 or Type 2 diabetes	•   Pregnant. •   Incapacity to give consent or to complete      the study questionnaires due to insufficient      language command or mental deficiencies. •   Concurrent severe psychological or      psychiatric disorders. •   Moderate to severe pain from other      causes that may confound assessment      or reporting of pain (e.g. spinal canal      stenosis). •   Central nervous lesions, which may      complicate somatosensory testing. •   Patients who are in the opinion of the      investigator unsuitable for participation in      the study.
Extreme phenotypes	•   ≥16 years with a set of symptoms that resemble those      seen on Paroxysmal Extreme Pain Disorder, Familial      Episodic Pain Syndrome or Erythromelalgia. •   Existing diagnosis of Paroxysmal Extreme Pain Disorder or      Familial Episodic Pain Syndrome or Erythromelalgia. •   Reduced pain sensibility. •   First degree relatives of patients who meet diagnostic      criteria for Paroxysmal Extreme Pain Disorder, Familial      Episodic Pain Syndrome, Erythromelalgia or inability to      experience pain. •   Patients who do not fulfil any of the exclusion criteria.	•   Pregnant. •   Incapacity to give consent or to complete      the study questionnaires due to insufficient      language command or mental deficiencies. •   Concurrent severe psychological or      psychiatric disorders, especially severe      claustrophobia. •   Moderate to severe pain arising as a      consequence of other disorders causing      pain but that are not associated with those      mentioned before as channelopathies. •   Central nervous system diseased that may      complicate the somatosensory testing. •   Patients who are in the opinion of the      investigator unsuitable for participation in      the study. •   Treatment or topical capsaicin cream/      ointment or Lidocaine patch within 30 days      prior to Day 1 on the skin area that will be      tested. •   Presence of oedema or any skin condition      at the ankle level that may interfere with the      microneurography procedure.